LA

Standard BioTools IncNASDAQ LAB Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.731

Micro

Exchange

XNAS - Nasdaq

LAB Stock Analysis

LA

Uncovered

Standard BioTools Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-33/100

Low score

Market cap $B

0.731

Dividend yield

Shares outstanding

79.064 B

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 523 full-time employees. The company went IPO on 2011-02-10. The firm has a portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines. The company provides reliable and repeatable insights into health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. The company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on translational and clinical research, including oncology, immunology, and immunotherapy. The firm offers instruments, such as Access Array, AccuLift, Biomark HD, Biomark X, C1, CyTOF XT, Flow Conductor, Helios a CyTOF System, Hyperion Imaging System, Hyperion+ Imaging System, and Juno. The company distributes its systems through its direct sales force and support organizations.

View Section: Eyestock Rating